Kalshi to let users bet on clinical trial outcomes and FDA drug reviews

Prediction market platform Kalshi has announced it is expanding into biotech, allowing users to place bets on clinical trial outcomes and FDA drug approval decisions. Bioethicist Jonathan Kimmelman of McGill University is raising concerns about the ethical implications of this move. The same podcast episode also discusses controversy surrounding an experimental Alzheimer's treatment from Biogen.